Navellier & Associates’s Immunogen Inc IMGN Stock Holding History

Navellier & Associates’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-92,538	Closed	-$876K	–	315
2018 Q3	$876K	Buy	+92,538	New	+$890K	0.11%	158

Other funds holding IMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Navellier & Associates's IMGN Position: Q4 2018 in Review

Navellier & Associates sold out of Immunogen Inc (IMGN) in Q4 2018, closing a stake of 92,538 shares — an estimated $876K sold.

Navellier & Associates first reported a position in IMGN in Q3 2018 and held it in 1 quarter. The position peaked at $876K in Q3 2018. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2018.

Navellier & Associates reported no remaining Immunogen Inc position as of Q4 2018 after selling out during the quarter.
Navellier & Associates sold 92,538 Immunogen Inc shares in Q4 2018, an estimated $876K.
Navellier & Associates first reported a position in Immunogen Inc in Q3 2018 and held it in 1 quarter.
Navellier & Associates's Immunogen Inc position peaked at $876K in Q3 2018.
200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2018.

Based on Navellier & Associates's 13F filing for Q4 2018, filed 15 Jan 2019.